ZA200200097B - Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof. - Google Patents

Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.

Info

Publication number
ZA200200097B
ZA200200097B ZA200200097A ZA200200097A ZA200200097B ZA 200200097 B ZA200200097 B ZA 200200097B ZA 200200097 A ZA200200097 A ZA 200200097A ZA 200200097 A ZA200200097 A ZA 200200097A ZA 200200097 B ZA200200097 B ZA 200200097B
Authority
ZA
South Africa
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
ZA200200097A
Other languages
English (en)
Inventor
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew George Popplewell
Andrew Paul Chapman
David John King
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200200097(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of ZA200200097B publication Critical patent/ZA200200097B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
ZA200200097A 2000-06-06 2002-01-04 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof. ZA200200097B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (1)

Publication Number Publication Date
ZA200200097B true ZA200200097B (en) 2003-01-06

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200097A ZA200200097B (en) 2000-06-06 2002-01-04 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.

Country Status (42)

Country Link
US (4) US7012135B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP3059314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP4064812B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20020047097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1289671C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2092A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR033978A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE451460T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU783756B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2010C019I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG66072B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0106682B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2707766C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (6) CY1109889T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ300737B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE60140738D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (4) DK2308975T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP024210A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (5) ES2337763T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR10C0015I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB0013810D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HU230561B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL147992A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2808B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2308975T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91674I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA01013440A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136603A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300982I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO334808B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ516596A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12282A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20020292A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL212738B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (4) PT2230308E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2303604C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2308975T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK288343B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201900227T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI353358B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001094585A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200200097B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ATE500273T1 (de) * 2002-03-20 2011-03-15 Ucb Pharma Sa Methoden zur analyse von antikörperdisulfidisomere
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
UA88599C2 (ru) 2002-05-02 2009-11-10 Уайт Холдингз Корпорейшн Коньюгат производное калихеамицина-антитело, способ его получения и способы лечения
US7601817B2 (en) 2002-05-28 2009-10-13 Ucb Pharma S.A. Antibody peg positional isomers, compositions comprising same, and use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
TWI430810B (zh) * 2002-07-19 2014-03-21 Abbott Lab S A ＴＮＦα相關病症之治療
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
EP1639011B1 (en) * 2003-06-30 2008-11-12 Domantis Limited Pegylated single domain antibodies (dAb)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
WO2006071091A1 (en) * 2004-12-29 2006-07-06 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
RU2425054C2 (ru) * 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
CA2609999C (en) * 2005-06-07 2017-05-30 Esbatech Ag Stable and soluble antibodies inhibiting tnf.alpha.
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2648582C (en) 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US20110002927A1 (en) * 2008-02-05 2011-01-06 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
KR101687032B1 (ko) * 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
SI3628686T1 (sl) 2008-06-25 2022-01-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
KR20210065201A (ko) 2008-06-25 2021-06-03 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US8383778B2 (en) * 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
AU2010310545C1 (en) 2009-10-23 2015-04-30 Amgen British Columbia Anti-GCC antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
AU2011223547B2 (en) 2010-03-04 2016-05-05 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CA3136084A1 (en) 2011-06-01 2012-12-06 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
BR112013032871B1 (pt) 2011-07-13 2022-09-27 Ucb Pharma S.A. Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
WO2013041673A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
MX357675B (es) 2012-08-13 2018-07-18 Genentech Inc Anticuerpos anti-jagged y métodos de uso.
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR102537099B1 (ko) 2014-12-22 2023-05-25 유씨비 바이오파마 에스알엘 단백질 제조 방법
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2760997C2 (ru) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Композиции и способы для лечения диабета 1 типа
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
RU2745748C2 (ru) * 2016-06-02 2021-03-31 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
SG11202004867WA (en) 2017-12-01 2020-06-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
JP2024534603A (ja) 2021-09-24 2024-09-20 エックスブレイン バイオファーマ エービー 組換えタンパク質を発現させるためのｄｎａ構築物及び宿主細胞
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5733742A (en) * 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE399809T1 (de) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
IS6217A (is) 2002-01-03
CY2019018I2 (el) 2020-05-29
HUP0202346A3 (en) 2004-11-29
JP5185143B2 (ja) 2013-04-17
GB0013810D0 (en) 2000-07-26
CZ2002837A3 (cs) 2002-05-15
CN1289671C (zh) 2006-12-13
CA2707766C (en) 2013-05-21
ECSP024210A (es) 2002-05-23
ES2600080T3 (es) 2017-02-07
TW200817430A (en) 2008-04-16
HU230561B1 (hu) 2016-12-28
MXPA01013440A (es) 2003-09-04
GB0128386D0 (en) 2002-01-16
AR033978A1 (es) 2004-01-21
IS2808B (is) 2012-09-15
GB2366800A (en) 2002-03-20
NO341218B1 (no) 2017-09-11
CZ300737B6 (cs) 2009-07-29
EP3059314A1 (en) 2016-08-24
US20030026805A1 (en) 2003-02-06
GB2366800B (en) 2005-01-19
TR201900227T4 (tr) 2019-02-21
NL300982I9 (nl) 2019-05-06
US20020151682A1 (en) 2002-10-17
BRPI0106682B1 (pt) 2020-10-13
ES2707714T3 (es) 2019-04-04
ES2230975A1 (es) 2005-05-01
PL353960A1 (en) 2003-12-15
CY1118220T1 (el) 2017-06-28
NZ516596A (en) 2004-07-30
BG106278A (bg) 2002-12-29
CA2380298A1 (en) 2001-12-13
AP2002002690A0 (en) 2002-12-31
HUP1600483A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-10-28
HUP1600016A2 (en) 2002-10-28
PL399351A1 (pl) 2012-12-17
SI2308975T1 (sl) 2016-11-30
PL212738B1 (pl) 2012-11-30
DK1287140T3 (da) 2010-04-19
PT3059314T (pt) 2019-02-01
DE10192353T1 (de) 2003-05-22
NO2014026I2 (no) 2018-02-14
HK1051385A1 (en) 2003-08-01
TWI353358B (en) 2011-12-01
JP2007105043A (ja) 2007-04-26
IS3016B (is) 2019-10-15
BE2010C019I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2020-08-20
NO2014026I1 (no) 2014-10-23
US7012135B2 (en) 2006-03-14
CY1114143T1 (el) 2016-07-27
HU230553B1 (hu) 2016-11-28
LT2308975T (lt) 2016-11-10
FR10C0015I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-04-16
HUP0202346A2 (en) 2002-10-28
CY1121173T1 (el) 2020-05-29
NL300982I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-05-01
JP2003535591A (ja) 2003-12-02
BR0106682A (pt) 2002-05-14
OA12282A (en) 2006-05-11
HK1148776A1 (en) 2011-09-16
NO20020554L (no) 2002-04-08
IL195085A0 (en) 2009-08-03
IL147992A0 (en) 2002-09-12
CY2019018I1 (el) 2020-05-29
EP1287140B1 (en) 2009-12-09
DE60140738D1 (de) 2010-01-21
HU230669B1 (hu) 2017-07-28
NO20131316L (no) 2002-04-08
EP2230308A1 (en) 2010-09-22
DK3059314T3 (en) 2019-02-18
WO2001094585A1 (en) 2001-12-13
SK3152002A3 (en) 2002-07-02
EP2308975B1 (en) 2016-08-10
US20060233800A1 (en) 2006-10-19
EP2308975A1 (en) 2011-04-13
SK288343B6 (sk) 2016-04-01
CA2380298C (en) 2010-09-28
MY136603A (en) 2008-10-31
JP4064812B2 (ja) 2008-03-19
AP2092A (en) 2010-02-28
JP2009171966A (ja) 2009-08-06
EP2230308B1 (en) 2013-01-23
US7186820B2 (en) 2007-03-06
CY1109889T1 (el) 2012-01-25
NO339282B1 (no) 2016-11-21
KR20020047097A (ko) 2002-06-21
US20080269465A1 (en) 2008-10-30
DE122010000027I1 (de) 2010-08-12
FR10C0015I2 (fr) 2011-12-30
PT1287140E (pt) 2010-03-08
SI2230308T1 (sl) 2013-06-28
TWI316088B (en) 2009-10-21
NO20160694A1 (no) 2002-04-08
US7977464B2 (en) 2011-07-12
ES2403217T3 (es) 2013-05-16
EP3059314B1 (en) 2018-10-24
PE20020292A1 (es) 2002-05-08
DK2230308T3 (da) 2013-05-06
EP1287140A1 (en) 2003-03-05
NO20020554D0 (no) 2002-02-04
BRPI0106682B8 (pt) 2021-05-25
SI1287140T1 (sl) 2010-04-30
IL147992A (en) 2009-06-15
PT2308975T (pt) 2016-11-14
NO334808B1 (no) 2014-06-02
JP4476989B2 (ja) 2010-06-09
AU783756B2 (en) 2005-12-01
CA2707766A1 (en) 2001-12-13
LU91674I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-03
US7402662B2 (en) 2008-07-22
ES2230975B2 (es) 2007-04-16
HUS1700013I1 (hu) 2017-08-28
CN1383450A (zh) 2002-12-04
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
LU91674I2 (fr) 2010-05-31
DK2308975T3 (da) 2016-10-31
PL218516B1 (pl) 2014-12-31
BG66072B1 (bg) 2011-01-31
RU2303604C2 (ru) 2007-07-27
ES2337763T3 (es) 2010-04-29
CY2010011I1 (el) 2012-01-25
PT2230308E (pt) 2013-05-03
AU6051101A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
HUS1700013I1 (hu) Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
ZA200300068B (en) Catalyst and process for the preparation of hydrocarbons.
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
WO2003005880A3 (en) Replikin peptides and uses thereof
IS6874A (is) 3,7-díasabísýkló[3.3.0]oktön og notkun þeirra í meðhöndlun á hjartsláttarglöpum
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer
HK1052013A (en) Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2001295337A1 (en) E. histolytica-specific antibodies and clinical uses thereof
GB0002552D0 (en) Virulence gene and protein, and their use
GB0003728D0 (en) Virulence gene and protein, and their use
GB0010587D0 (en) Virulence gene and protein, and their use
GB0003731D0 (en) Virulence gene and protein, and their use
GB0003732D0 (en) Virulence gene and protein, and their use
GB0003730D0 (en) Virulence gene and protein, and their use
GB0003735D0 (en) Virulence gene and protein, and their use
GB0010585D0 (en) Virulence gene and protein, and their use
GB0003733D0 (en) Virulence gene and protein, and their use
GB0003729D0 (en) Virulene gene and protein, and their use
GB0003736D0 (en) Virulence gene and protein, an their use